Results 191 to 200 of about 36,741 (290)

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Neighborhood social environment and patterns of adherence to oral hypoglycemic agents among patients with type 2 diabetes mellitus. [PDF]

Fam Community Health, 2015
de Vries McClintock HF, Wiebe DJ, OʼDonnell AJ, Morales KH, Small DS, Bogner HR.   +5 more
europepmc   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan, Hongwei Jiang, Yi Feng, Suijun Wang, Jin Zhang, Zhongjing Wang, Yusen Zhou, Fangqiong Li, Zhanhui Zhang, Yaming Li, Liming Chen   +10 more
wiley   +1 more source

Analysis of the consumption of oral hypoglycemic agents within 2014-2017 at the pharmaceutical market of Ukraine

, 2018
Л. В. Яковлєва, A. K. Yakovlieva, О. Г. Бердник   +2 more
openalex   +2 more sources

Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1234-1246, February 2026.
Abstract Aims This study investigates the relationship between multisensory (visual, somatosensory, and olfactory) dysfunction and cognitive decline in Type 2 diabetes (T2D), with a particular focus on the mediating role of olfactory dysfunction. Methods We used resting‐state fMRI to assess seed‐based functional connectivity from the primary sensory ...
Qian Li, Xin Li, Yan Bi, Jiaming Lu, Yi Zhang, Min Wu, Xinyi Shen, Zhengyang Zhu, Xin Zhang, Yining Chao, Zhou Zhang, Wen Zhang, Bing Zhang   +12 more
wiley   +1 more source

Increased HbA1c relative to actual glycemic control in patients treated with sodium-glucose cotransporter 2 inhibitors. [PDF]

J Diabetes Investig
Mizutani K, Uenishi E, Onoue T, Maeda R, Suzuki K, Handa T, Kobayashi T, Iwama S, Miyata T, Sugiyama M, Hagiwara D, Suga H, Okazaki M, Hashizume A, Arima H.   +14 more
europepmc   +1 more source

Search for New Oral Hypoglycemic Agents. Part V

, 1963
S. S. Tiwari, Anand Swaroop
openalex   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source